$2.05
(Market cap
$41,317 Mln
Recently Viewed
Clear AllMarket cap
$41,317 Mln
Revenue (TTM)
$3,714 Mln
P/E Ratio
133.5
P/B Ratio
52.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$314 Mln
ROE
0.7 %
ROCE
12.9 %
Industry P/E
--
EV/EBITDA
62.9
Debt to Equity
1.6
Book Value
$5.8
EPS
$2.3
Face value
--
Shares outstanding
133,427,910
CFO
$-3,580.08 Mln
EBITDA
$-5,459.67 Mln
Net Profit
$-6,481.57 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alnylam Pharmaceuticals (ALNY)
| -21.4 | 0.1 | -15.5 | 32.1 | 14.3 | 17.8 | 15.8 |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P 100
| 1.3 | 10.1 | 2.5 | 37.6 | 22.9 | 13.3 | 14.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Alnylam Pharmaceuticals (ALNY)
| 69.0 | 22.7 | -19.5 | 40.1 | 30.5 | 12.9 | 58.0 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alnylam Pharmaceuticals (ALNY)
|
312.6 | 41,317.3 | 3,713.9 | 313.8 | 11.2 | 73.3 | 133.5 | 52.4 |
| 143.1 | 31,186.3 | 606.4 | -1,276.8 | -196.7 | -249.3 | -- | 42.2 | |
| 74.6 | 12,506.7 | 944.0 | -381.0 | -31.6 | -70.7 | -- | 25.6 | |
| 161.3 | 29,945.3 | 16,310.0 | 1,360.0 | 14.2 | 21.6 | 21.9 | 4.4 | |
| 54.7 | 21,304.7 | 1,944.0 | -2,822.0 | -142.4 | -28.9 | -- | 2.5 | |
| 131.4 | 13,402.6 | 2,860.5 | 478.6 | 24.1 | 16.4 | 28.5 | 4.1 | |
| 754.6 | 79,350.1 | 14,342.9 | 4,504.9 | 36.8 | 14.9 | 18.1 | 2.5 | |
| 23.3 | 19,500.6 | 0.0 | -1,079.6 | -- | -206.1 | -- | 29.6 | |
| 571.8 | 25,787.3 | 3,182.7 | 1,334.7 | 54.1 | 19.7 | 21.1 | 3.6 | |
| 437.8 | 112,223.5 | 12,074.6 | 3,953.2 | 38.4 | 22.5 | 28.8 | 5.9 |
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary... transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts. Read more
CEO & Director
Dr. Yvonne L. Greenstreet M.B.A., MBChB
CEO & Director
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Alnylam Pharmaceuticals Inc (ALNY) is $312.63 (NASDAQ) as of 23-Apr-2026 10:40 EDT. Alnylam Pharmaceuticals Inc (ALNY) has given a return of 14.31% in the last 3 years.
The P/E ratio of Alnylam Pharmaceuticals Inc (ALNY) is 133.47 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
172.73
|
68.67
|
|
2024
|
-108.78
|
451.03
|
|
2023
|
-54.61
|
-108.97
|
|
2022
|
-25.90
|
-185.14
|
|
2021
|
-23.82
|
34.53
|
The 52-week high and low of Alnylam Pharmaceuticals Inc (ALNY) are Rs 495.55 and Rs 238.62 as of 23-Apr-2026.
Alnylam Pharmaceuticals Inc (ALNY) has a market capitalisation of $ 41,317 Mln as on 17-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Alnylam Pharmaceuticals Inc (ALNY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.